The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better tuberculosis treatment. Our market-focused approach puts Brazil, Russia, India, China, and South Africa (the BRICS) governments in the driver’s seat—empowering them to send a powerful signal to private-sector pharmaceutical companies about the innovation they value and at the kind of price they are willing to consider.
OHE’s Professor Nancy Devlin will be leaving OHE to take up a new role at the University of Melbourne, Australia, from January 2019.
Nancy will be Professor of Health Economics and Director of the Centre of Health Policy in the Melbourne School of Population and Global Health. The Centre of Health Policy comprises research units in Demography and Ageing; Evaluation and Implementation Science; Public Health and Law; Cancer Health Services Research; and Health Economics (the latter of which Nancy will also lead).
Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.